Advertisement
Australia markets closed

  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     

  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     

  • AUD/USD

    0.6521
    +0.0021 (+0.32%)
     

  • OIL

    82.97
    +0.16 (+0.19%)
     

  • GOLD

    2,334.10
    -4.30 (-0.18%)
     

  • Bitcoin AUD

    98,295.89
    -4,177.88 (-4.08%)
     

  • CMC Crypto 200

    1,389.92
    +7.35 (+0.53%)
     

  • AUD/EUR

    0.6082
    +0.0011 (+0.19%)
     

  • AUD/NZD

    1.0952
    +0.0010 (+0.09%)
     

  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     

  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     

  • FTSE

    8,077.27
    +36.89 (+0.46%)
     

  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     

  • DAX

    17,981.83
    -106.87 (-0.59%)
     

  • Hang Seng

    17,275.64
    +74.37 (+0.43%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

Regeneron, Sanofi Drop After-Hours as Covid-19 Vaccine Trial Halted

Investing.com
·1-min read

By Christiana Sciaudone

Investing.com -- Shares of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)fell 2.6% and Sanofi (PA:SASY)fell 1.7% in after-hours trading Thursday after the companies said phase 3 of their Covid-19 vaccine trial did not meet endpoints and they would halt the U.S. trial.

Kevzara (sarilumab) 400 mg did not meet primary and key secondary endpoints compared to a placebo. Minor positive trends were seen but were not statistically significant, and countered by negative trends in a subgroup of critical patients.

A trial of patients who received a dose of 800 mg of Kevzara was also halted.

ADVERTISEMENT

A separate Sanofi-led trial outside the U.S. in hospitalized patients with severe and critical Covid-19 using a different dosing regimen is ongoing.

Related Articles

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.36%

Wirecard debt that facilitated Softbank investment put up for auction

Japan asks U.S. to extradite men accused of helping ex-Nissan boss Ghosn flee